Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hepatectomy is still the most important treatment for HCC.High recurrence rate mostly influence it's prognosis, especially for the patient with tumor >5cm, multiple tumor and who cannot accept R0 resection.Our retrospective study showed sustained released 5-FU implanted into the liver incisal margin after tumor was resected could reduce the recurrence rate of HCC after liver resection.According to this, we proceed this RCT to prospectively observe the effect of sustained released 5-FU,and we also want to know whether combined with sustained released cisplatin will get better effect in preventing the tumor recurrence,especially in short time after liver resection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eastern Hepatobiliary Surgery Hospital
• Treatments: Cisplatin; Fluorouracil

Criteria

Inclusion Criteria:

1. tumor >5cm;

2. multiple tumor located in one liver lobe;

3. margin of tumor is not clear;

4. cutting edge to tumor <1cm;

5. portal vein branch invasion;

6. without extra-liver metastasis;

7. patient's liver function and condition is able to accept hepatectomy.

Exclusion Criteria:

1. single tumor <=5cm;

2. multiple tumor located more than in one liver lobe;

3. margin of tumor is clear;

4. cutting edge to tumor >=1cm;

5. portal vein stem invasion

6. extra-liver metastasis;

7. patient's liver function and condition cannot accept hepatectomy.